New data from observational studies in the UK shows that patients with type 2 diabetes experience greater reduction of HbA1c levels when using Victoza compared to Byetta (exenatide) and DPP-4 inhibitors. Victoza also proved to be cost effective when used in routine primary care according to current UK type 2 diabetes treatment guidelines.
According to the study more patients appeared to favor a drug with a liraglutide-like profile (Victoza), which is given by injection, over a drug with a sitagliptin-like profile (Januvia), which is given orally.
The study looked at data from 1,114 type 2 diabetes patients from primary care practices in the UK and assessed the clinical efficacy and patient preference with respect to liraglutide, exenatide and DPP-4 inhibitors.
Based on observed treatment effects, the United Kingdom Prospective Diabetes Study (UKPDS) 68 risk equations were applied over a 20-year time horizon to calculate cost-effectiveness. The observed cost/QALY (Quality Adjusted Life Years) vs baseline for patients receiving liraglutide, exenatide or a DPP-4 inhibitor was £16,505, £16,648 and £20,661, respectively. Costs were calculated using the most commonly prescribed DPP-4 inhibitor, sitagliptin.
Source: Novo Nordisk
